New analysis digs into ocrelizumab's effect on brain inflammation in progressive MS
NCT ID NCT05974852
First seen Mar 20, 2026 · Last updated May 15, 2026 · Updated 10 times
Summary
This study re-examines MRI scans from 732 people with primary-progressive multiple sclerosis who took part in the ORATORIO trial. Researchers want to see if ocrelizumab changes a specific brain area called the choroid plexus, which may be linked to inflammation. The goal is to better understand how the drug works, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Buffalo Neuroimaging Analysis Center
Buffalo, New York, 14203, United States
Conditions
Explore the condition pages connected to this study.